The Peptide Operator's Tax Guide: What 280E, IRC 162, and IRC 199A Actually Say

One of the most common questions we get from new peptide operators sounds like this: "We sell BPC-157 and TB-500 online. Our last accountant treated us like a cannabis dispensary on the tax return. Are we actually exposed to 280E?" The answer is no. Peptides are not controlled substances within the meaning of Schedule I or Schedule II of the federal Controlled Substances Act, and Section 280E of the Internal Revenue Code does not apply to a business that sells, compounds, or administers them.

That answer rests on the same statutory clause we have been arguing about cannabis for years. Section 280E denies deductions and credits to any trade or business "trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act)." The phrase "within the meaning of" is doing all the work. For cannabis, that phrase is the entire fight. The DEA still lists cannabis on Schedule I even as HHS has recommended rescheduling and state programs operate openly - and we maintain that listing fails the statutory criteria, which is exactly why the phrase matters. For peptides, the same phrase produces a clean answer in the operator's favor from day one. The substances are not scheduled. The trigger language is not satisfied. The section does not apply.

What follows is the working tax framework we use for peptide clients at Calyx CPA. It is not a sales pitch and it is not a hedge. It is the position we take on returns, in planning conversations, and in audit defense for online research-use-only retailers, peptide-focused medical spas, 503A compounding pharmacies, and 503B outsourcing facilities. We maintain that this is the correct reading of the statute, and we prepare returns accordingly.

Peptides Are Not Controlled Substances (And Why That Matters)

The federal Controlled Substances Act organizes drugs into five schedules. Schedule I is reserved for substances the government deems to have no accepted medical use and high abuse potential; the DEA currently lists heroin, LSD, MDMA, psilocybin, and cannabis there - though we have argued at length that cannabis and psilocybin fail those criteria. Schedule II contains substances with accepted medical use but high abuse potential: cocaine, methamphetamine, oxycodone, fentanyl, and most other opioid analgesics. Schedules III through V step down from there based on abuse potential and dependence liability.

The peptides driving the current market are not on any of these schedules. BPC-157, TB-500, GHK-Cu, ipamorelin, and CJC-1295 are research peptides with no federal scheduling status. Semaglutide and tirzepatide are FDA-approved GLP-1 receptor agonists distributed under prescription and similarly unscheduled. None of these molecules meets the Schedule I or Schedule II definition. None of them triggers 280E.

Relying on the statutory language, the analysis stops there. Section 280E disallows deductions only for businesses trafficking in substances within the meaning of Schedule I or II. A business selling unscheduled peptides is not such a business. The disallowance does not attach. This is the same statutory reading we apply to cannabis clients, where the fight is live because the DEA still lists cannabis on Schedule I - a listing we have publicly challenged. For peptide clients, the reading produces a defensible, full-deduction position with no ambiguity.

What Peptide Operators Get to Deduct (Everything)

Because 280E is out of the picture, peptide operators are entitled to the same tax treatment as any other lawful trade or business. That treatment is broader than most new operators realize, and broader still than what their cannabis-adjacent advisors tend to assume.

Under IRC 162, ordinary and necessary business expenses are fully deductible. That includes rent, payroll, advertising, merchant processing fees, professional fees, software subscriptions, insurance premiums, travel, continuing education, and the dozens of smaller line items that make up an operating P&L. None of these are touched by 280E, because 280E does not apply.

Under IRC 199A, pass-through operators are entitled to the 20% qualified business income deduction, subject to the W-2 wage and qualified property limits that apply above the income threshold. For a peptide LLC taxed as an S-corp generating $400,000 of qualified business income, that deduction is meaningful - it is the difference between paying tax on $400,000 and paying tax on $320,000 at the owner level. The IRS continues to deny this deduction to cannabis operators on plant-touching income - a position we have publicly challenged. Peptide operators face no such fight.

Standard depreciation rules apply. Section 179 expensing is available up to the annual limit. Bonus depreciation is available at the percentage in effect for the year placed in service. For 503B outsourcing facilities and for peptide clinic build-outs that involve significant tenant improvements, we routinely recommend cost segregation studies to accelerate depreciation on five-year and fifteen-year property components that would otherwise default to a 39-year recovery period.

The point worth stating directly: the deductions we fight to preserve for our cannabis clients - payroll, rent, marketing, professional fees, depreciation - are simply available to peptide clients. There is no fight. There is no carve-out. There is no need for a 471(c) workaround. Ordinary trade or business tax treatment applies.

COGS and Inventory Accounting Under IRC 471

Inventory accounting under IRC 471 follows the standard rules. Operators with average annual gross receipts below the section 471(c) small business threshold (currently approximately $29 million) have flexibility in how they account for inventory, including the option to treat inventory as non-incidental materials and supplies or to conform to the method used in the taxpayer's applicable financial statement.

For 503A compounding pharmacies and 503B outsourcing facilities, COGS includes active pharmaceutical ingredient costs, sterile compounding supplies, USP 797 and 800 compliance overhead allocable to production, FDA-registered facility costs in the case of 503B operations, and direct compounding labor. These are real, substantial costs and they belong in COGS, properly documented and properly allocated.

For online research-use-only retailers, COGS includes product acquisition cost, inbound freight, fulfillment labor or third-party fulfillment fees, packaging, and any quality testing performed before shipment. The disclaimer on the website does not change the accounting. Income from the sale of peptides is ordinary trade or business income. The cost of acquiring and shipping those peptides is COGS. Both sides of that equation are recognized.

Entity Structure Decision Tree

The right entity structure depends on the operating model. We walk every new peptide client through the following branches in the first planning conversation. Each branch has a dedicated spoke article on the Calyx site that goes deeper on formation mechanics, payroll setup, and state-specific compliance.

Online research-use-only retailer. Start as a single-member or multi-member LLC. Once distributable profits comfortably exceed a reasonable W-2 baseline for the active owner - generally somewhere north of $80,000 to $100,000 of net income, depending on role and market - elect S-corp treatment under IRC 1362 to begin shifting earnings out of self-employment tax. Wyoming and Delaware formation are common for asset protection and privacy reasons, paired with foreign qualification in any state where the operator has a physical presence or sales tax nexus.

Peptide clinic in a Corporate Practice of Medicine state. States including California, Texas, New York, New Jersey, Illinois, Ohio, Pennsylvania, Oregon, and Washington restrict the practice of medicine to licensed physicians. In those states, the clinical entity must be a professional corporation or professional limited liability company owned by a licensed physician. The management services organization - owning the brand, the lease, the equipment, the marketing, and the non-clinical staff - is a separate LLC owned by the business operators. The MSO contracts with the PC under a management services agreement at arm's length terms. This is the only defensible structure in a CPOM state, and it is non-negotiable in our planning work.

Peptide clinic in a non-CPOM state. A single LLC or PLLC is typically sufficient, with an S-corp election once income justifies it. The CPOM separation is not required, which simplifies the structure and reduces the ongoing legal and accounting overhead.

503A compounding pharmacy. A professional association, professional corporation, or PLLC owned by the licensed pharmacist of record, with an S-corp election. State pharmacy board rules govern ownership and naming. The S-corp election handles the self-employment tax planning.

503B outsourcing facility. C-corp is typical. The scale of capital investment, the FDA registration burden, the institutional customer base, and the path to outside investment all point toward a C-corp structure. The double taxation cost is real but manageable with retained earnings deployed into facility expansion and qualified small business stock planning where applicable.

The Three Tax Risks Peptide Operators Actually Face

280E is not on this list. The risks that are on this list are the ones we see produce real assessments, real penalties, and real cash drag for operators who did not plan for them.

Sales tax nexus. Since South Dakota v. Wayfair in 2018, physical presence is no longer required to create sales tax nexus. Economic nexus thresholds - commonly $100,000 in gross receipts or 200 transactions per year into a state, though the specifics vary - trigger registration and remittance obligations. A peptide retailer shipping nationally from a single warehouse can easily have collection obligations in twenty or thirty states by year two. The cost of not addressing this on the front end is back assessments plus penalties and interest, which can substantially exceed the original tax owed once several years stack up. The fix is a multi-state nexus study, voluntary disclosure agreements where exposure already exists, and a sales tax software stack integrated into the order management system.

Self-employment tax overpayment. An LLC taxed as a partnership or a sole proprietorship pays self-employment tax on the full net earnings of the business. For an active owner clearing $300,000 of net income, that is real money - often north of $10,000 a year of incremental tax that an S-corp election would have eliminated on the distribution portion of compensation. The S-corp election is the standard planning lever. The discipline required is reasonable compensation: the W-2 paid to the owner-employee must be defensible against IRS challenge, supported by industry compensation data, role, hours, and the nature of services performed. We document this analysis annually for every S-corp client.

Reclassification risk. A peptide that is unscheduled today can be moved to a federal schedule by DEA action. If that happens mid-year, the tax landscape changes for any operator selling that specific molecule. We track DEA scheduling activity and emergency scheduling petitions for our peptide clients as part of the ongoing service. As of this writing, no peptide commonly sold in the operator market is on Schedule I or Schedule II. The FDA Category 2 listing for BPC-157 in 2023 closed off 503A compounding for that molecule, but it did not schedule the substance - it can still be sold research-use-only without 280E exposure. The FDA's February 2025 resolution of the semaglutide shortage and October 2024 resolution of the tirzepatide shortage similarly closed off most 503A compounding of those GLP-1s, with the narrow exception of documented clinical-difference compounding. None of those FDA actions triggers 280E. They are regulatory developments, not scheduling actions.

A Note on HSA, FSA, and Patient Payment

Operators running clinics ask about HSA and FSA eligibility constantly, and the answer matters for patient acquisition and pricing. GLP-1s prescribed for type 2 diabetes - Ozempic, Mounjaro - are typically eligible for HSA and FSA reimbursement without additional documentation. GLP-1s prescribed for weight loss - Wegovy, Zepbound - generally require a Letter of Medical Necessity under most plan administrators as of 2026. BPC-157, TB-500, NAD+, and similar wellness peptides are not HSA or FSA eligible. We make sure clinic clients understand this before they build payment flows around an assumption that does not hold.

What Calyx Does for Peptide Operators

The work is concrete and it is ongoing. Entity formation aligned to Corporate Practice of Medicine doctrine and state pharmacy board rules. Multi-state sales tax registration, voluntary disclosure where back exposure exists, and ongoing remittance through a software stack we configure and monitor. S-corp election filing, payroll setup through a provider we vet, and annual reasonable compensation analysis documented to audit-defense standard. Monthly accounting with proper COGS allocation between production overhead and operating expense. Federal and state income tax return preparation, including state apportionment for multi-state operators. Audit representation by our team if the IRS or a state department of revenue raises a question on a return we prepared.

A Note on 280E Carryover Mistakes

We have onboarded peptide operators whose prior preparers treated returns as 280E-exposed. The reasons vary. Sometimes the preparer was cannabis-adjacent and applied the same framework out of habit. Sometimes the preparer was unfamiliar with the substances and chose what felt like the conservative position. The result in either case is the same: deductions that the operator was entitled to take were disallowed on the return, and the operator overpaid federal and state tax.

Where the statute of limitations is still open - generally three years from the original filing date, longer in cases of substantial omission - we file Form 1040X or Form 1120X amended returns to recover the overpaid tax, with interest. We have done this for clients to material effect. If your prior returns treated peptide income as 280E-exposed, the returns are wrong, and they are correctable.

The Position, Restated

Peptides are not controlled substances within the meaning of Schedule I or Schedule II of the federal Controlled Substances Act. Section 280E does not apply. Peptide operators are entitled to the full ordinary tax treatment of any other lawful trade or business: full IRC 162 deductibility, full IRC 199A qualified business income eligibility, standard depreciation and Section 179, and standard IRC 471 inventory accounting. The regulatory framework around FDA 503A and 503B is real and it shapes operations, but it does not change the tax answer. Research-use-only disclaimers do not change the tax answer either. Ordinary income, ordinary deductions, ordinary returns.

If you are running a peptide business and your current preparer is hedging, or has applied 280E out of habit, or has not addressed your multi-state sales tax exposure, we should talk. The position we take is defensible. The strategies we deploy are the same ones we use for any other professional services or specialty retail client, with the regulatory layer that peptide operators specifically need. Contact us through the Calyx CPA site to start a conversation.

This article is intended for informational purposes only and does not constitute legal, tax, or medical advice.